• Publications
  • Influence
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk
TLDR
Oral but not transdermal ERT is associated with risk of VTE in postmenopausal women, and data suggest that transder mal ERT might be safer than oral ERT with respect to thrombotic risk. Expand
Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study
TLDR
Oral but not transdermal estrogen is associated with an increased VTE risk, and data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect toThrombotic risk. Expand
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis
TLDR
Oral oestrogen increases the risk of venous thromboembolism, especially during the first year of treatment, and transdermal oestrogens may be safer with respect to thrombotic risk. Expand
Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
TLDR
Oral estrogen/progesterone replacement therapy may result in coagulation activation and increased fibrinolytic potential, whereas opposed transdermal estrogen appears without any substantial effects on hemostasis. Expand
Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological
TLDR
Fibrinogen level and, to a lesser extent, factor VII and PAI-1 activity were higher in Northern Ireland than France after adjustment for the main cardiovascular risk factors, and these geographical variations are consistent with the 2 to 3-fold higher incidence of myocardial infarction in NorthernIreland than France. Expand
Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration
TLDR
In contrast to oral estrogen, transdermal estrogen does not confer additional risk on women who carry a prothrombotic mutation, and the safety of transDermal estrogen has to be confirmed in randomized trials. Expand
Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000
TLDR
In this large pooled analysis of case–control and cohort studies investigating in adults the association between each variant and VTE, no effect was found for C677T MTHFR on VTE; FVL and PT20210A were confirmed to be moderate risk factors. Expand
Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study
TLDR
Oral estrogen therapy increases venous thromboembolism risk among postmenopausal women using hormone therapy and route of estrogen administration and concomitant progestogens type are 2 important determinants of thrombotic risk. Expand
...
1
2
3
4
5
...